GHK-Cu: What It Is, Where to Get It Prescribed, and What It Costs

GHK is a tripeptide — glycine, histidine, lysine — and GHK-Cu is that tripeptide with a copper ion bound to it. It was first described in 1973, in a Nature: New Biology paper, as a component of human plasma that prolonged the survival of liver cells in culture. It occurs naturally in plasma, saliva and urine, and the reviews describe its plasma concentration falling with age, from roughly 200 ng/mL in a person's twenties to around 80 ng/mL by their sixties. Whether that decline causes anything, or is simply a marker of ageing, has not been shown. The same GHK motif also sits inside larger proteins, including collagen and SPARC, which is the basis for the idea that GHK is a signal released when tissue is being remodelled.

GHK binds copper(II) with high affinity, and it is the copper complex — not the bare tripeptide — that most of the research is built around. Copper is a cofactor for the enzymes that cross-link collagen and elastin and for antioxidant defence. The proposed role of GHK is as a carrier: holding copper in a form that is not free and reactive, and delivering it to cells that need it. The copper in a dose is small and chelated, unlike copper taken as a mineral supplement.

GHK-Cu is not a hormone and does not act on hormone receptors. It is not a growth hormone secretagogue and does not change growth hormone, IGF-1 or testosterone. It is not a steroid, a filler, a retinoid or an exfoliant. And the injectable is not the cream: most of what is written online about "GHK-Cu results" refers to topical cosmetic use, and those findings do not transfer automatically to an injection.

The oldest and best-replicated finding. A 1988 FEBS Letters paper reported that GHK-Cu stimulated collagen synthesis in cultured human fibroblasts at very low concentrations, and later cell work extended this to elastin, proteoglycans and glycosaminoglycans. In rats, a 1993 Journal of Clinical Investigation paper reported increased accumulation of connective tissue in experimental wound chambers treated with the copper complex. This is the mechanism the skin and wound research rests on.

Building tissue is only half of remodelling; the other half is clearing damaged matrix. Two papers from the same group — Journal of Investigative Dermatology 1999 in rat wounds, Life Sciences 2000 in fibroblast cultures — describe GHK-Cu modulating matrix metalloproteinase expression and activation, and the reviews describe it shifting the balance between MMPs and their tissue inhibitors. The proposed picture is a peptide that tunes turnover in both directions rather than simply adding collagen.

A 1994 Journal of Cell Biology paper reported that copper-binding GHK fragments released from SPARC stimulated angiogenesis — new blood-vessel growth — in vitro and in vivo. This is part of the wound-healing story, and it is also why a cancer history is something to raise with your physician, as it is with BPC-157.

A 2012 review in Oxidative Medicine and Cellular Longevity collected cell and animal work describing GHK-Cu reducing oxidative stress markers, and a 2012 Acta Poloniae Pharmaceutica paper reported the copper complexes reducing TNF-alpha-driven IL-6 secretion in cultured human dermal fibroblasts. The injected mouse work below sits on the same theme. These are cell and animal observations about signalling, not evidence about inflammatory conditions in people.

A 2012 Genome Medicine paper is the reason GHK is discussed as more than a skin peptide. Using the Broad Institute's Connectivity Map, the authors found that GHK's gene-expression signature ran opposite to the signature of emphysema-related lung destruction, and in cultured lung fibroblasts from patients they reported GHK restoring contraction and collagen remodelling. The 2018 International Journal of Molecular Sciences review argues from the same database that GHK alters expression of a large number of genes rather than acting through one pathway. That is a computational and cell-level finding, not a demonstration in a person.

Cosmetic-science studies in human volunteers have evaluated GHK-Cu creams, mostly in women with photoaged facial skin over 8 to 12 weeks, and reported changes in skin density, thickness, firmness, fine lines and clarity measured by instruments and by dermatologists. Most of that work appeared in conference proceedings and industry-funded reports rather than peer-reviewed journals; the 2015 BioMed Research International review summarises it. A 2006 Archives of Facial Plastic Surgery paper examined topical copper tripeptide after CO2 laser resurfacing in a small number of patients. In short: real human data, small studies, topical route, cosmetic endpoints.

The most clinically serious human study is a 1994 paper in Wound Repair and Regeneration, which reported improved closure of ulcers in patients with diabetes treated with a topical GHK-Cu gel. Animal wound work reports faster closure and better collagen organisation with topical or locally applied GHK-Cu. Again, this is skin-surface application, not systemic injection.

A 2007 Archives of Pharmacal Research paper reported that a tripeptide-copper complex affected the growth of human hair follicles kept in culture, and the reviews describe follicle-size and growth-phase effects in animal models. There is no human trial of GHK-Cu, topical or injected, with hair growth as its endpoint. Anything more specific than "follicle biology in the dish" overstates it.

This is the body of work most relevant to a subcutaneous injection, and it is entirely preclinical. Mouse studies describe intraperitoneal or systemic GHK-Cu reducing inflammatory markers and structural damage in models of acute lung injury (Oncotarget 2016), bleomycin-induced fibrosis (Life Sciences 2020) and cigarette-smoke emphysema (Frontiers in Molecular Biosciences 2022). They establish that systemic GHK-Cu does something measurable in rodents, not what it does in a person.

This is the part to understand before starting. There are no randomised controlled trials of injectable GHK-Cu in humans. The human evidence that exists is topical: cosmetic studies in photoaged skin and one study of a topical gel in diabetic ulcers. Prescribers who use the injectable for skin, hair and tissue-quality goals have clinical experience, and that is what the "realistic expectations" below are drawn from.

The honest framing is: well characterised in cells and animals, human-studied as a topical, used clinically as an injection on the strength of mechanism plus experience. That is a reasonable basis for a physician to prescribe it; it is not "proven to work when injected."

• It does not establish that subcutaneous GHK-Cu reaches skin, hair follicles or connective tissue at a concentration that does anything; that human pharmacokinetic work has not been published.
• It does not establish an effect size or a timeline for the injectable in people. Everything in that direction is prescriber experience.- It does not establish long-term safety data for continuous injectable use over years.
• It does not establish efficacy for any condition as an FDA-approved treatment. It is not approved for anything.

Most people notice nothing in this window, and that is expected. Collagen synthesis and matrix turnover are slow processes; nothing in the research suggests an acute effect to feel. Injection-site reactions, if they occur, show up here.

This is where prescribers describe changes in skin texture and hydration, where they are reported at all. It lines up loosely with the 8-to-12-week windows of the topical cosmetic studies, though those were a different route. A vial covers about four weeks at Monday-through-Friday dosing, so this window spans two fills.

Hair-related goals are described by prescribers as slower than skin goals, because the hair cycle itself runs in months. Anyone expecting a visible hair change inside a single vial is expecting something no evidence supports. There is no withdrawal and no rebound described in the literature after a course ends.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication, and your physician sets it.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. GHK-Cu solutions are blue — that is the copper complex, not a contaminant.

The directions specify weekdays, not seven days. Twenty doses at five per week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile. The two-day break is a prescribing convention; there is no human pharmacokinetic study of injected GHK-Cu to derive a schedule from.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. A marked colour change is a reason to call the pharmacy rather than inject.

Different jobs. BPC-157 is described around angiogenesis, nitric-oxide signalling and tendon fibroblast migration, and prescribers use it for injury recovery. GHK-Cu is described around collagen synthesis, matrix remodelling and copper delivery, and prescribers use it for skin, hair and connective-tissue quality. Neither has human trial evidence for the injectable route. They are frequently combined rather than chosen between, which is what the KLOW blend and GLOW are.

Single-agent GHK-Cu is the choice when skin or connective tissue is the only goal, or when a physician wants to add one compound at a time. The KLOW blend and GLOW add BPC-157 and TB-500; the RADIANCE blend pairs GHK-Cu with tesamorelin; the ETERNAL blend adds epithalon. A blend means one injection instead of several, at the cost of not knowing which component did what.

The topical route is where the human evidence lives, and cosmetic GHK-Cu creams are sold without a prescription. The injectable is a prescription medication with animal data and clinical experience behind it; no study has compared the two. Prescribers who use the injectable are reasoning from systemic exposure, which is plausible but untested.